Clinical Pipeline Shattuck Labs is advancing a first-in-class DR3 antagonist antibody (SL-325) targeting the TL1A/DR3 pathway for IBD and inflammatory autoimmune diseases, with upcoming developments such as SL-846 (DR3 x IL-23 bispecific) indicated for future timelines. This suggests opportunities to engage in partnerships or licensing discussions around novel TNF receptor targeting assets and potential collaboration on bispecific formats.

Leadership and Financing The company has strengthened its leadership and governance with recent Board additions including industry veteran Daniel Baker and OrbiMed affiliate Mona Ashiya, alongside a significant funding round totaling around $403M. This indicates a mature platform open to strategic deals, co-development, or commercial partnerships with established biopharma and investment-backed ventures.

Clinical and Regulatory Momentum Shattuck has actively engaged with key scientific and investor forums (ECCO, Piper Sandler Novel Targets in Immunology) and reported positive preclinical GLP toxicology data for SL-325, signaling ongoing clinical and regulatory progress that can be leveraged for partner outreach, joint development discussions, and early access to advisory networks.

Geographic Footprint With offices in Austin and Durham, plus participation in national and international events, Shattuck demonstrates a U.S. focus with broad scientific collaboration potential. This geographic positioning may facilitate co-development and contract research opportunities, as well as regional partnerships for testing, manufacturing, and eventual commercialization.

Technology and Operations Shattuck employs a mixed tech stack including cloud platforms and enterprise tools (Google Cloud, Microsoft Azure, NetSuite, Shopify, Drupal) aligned with scalable research operations and possible future commercialization activities. This technical foundation supports partnerships around data management, analytics, and manufacturing scale-up, offering entry points for CRO/CMO collaborations and technical due diligence synergies.